• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by McKesson Corporation

    5/20/25 4:18:27 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email
    FWP 1 mckessoncorporation-pricin.htm FWP Document
    Filed Pursuant to Rule 433
    Registration Statement No. 333-269523

    Pricing Term Sheet
    MCKESSON CORPORATION
    $650,000,000 4.650% Notes due 2030
    $650,000,000 4.950% Notes due 2032
    $700,000,000 5.250% Notes due 2035
    Issuer:McKesson Corporation
    Expected Ratings (Moody’s / S&P / Fitch)*:A3 (Stable) / BBB+ (Positive) / A- (Stable)
    Security Title:4.650% Notes due 20304.950% Notes due 20325.250% Notes due 2035
    Principal Amount:$650,000,000$650,000,000$700,000,000
    Maturity Date:May 30, 2030May 30, 2032May 30, 2035
    Interest Payment Dates:Semi-annually on May 30 and November 30, of each year, commencing November 30, 2025Semi-annually on May 30 and November 30, of each year, commencing November 30, 2025Semi-annually on May 30 and November 30, of each year, commencing November 30, 2025
    Interest Rate:4.650% per year4.950% per year5.250% per year
    Benchmark Treasury:
    UST 3.875% due April 30, 2030
    UST 4.000% due April 30, 2032
    UST 4.250% due May 15, 2035
    Benchmark Treasury Price and Yield:
    99-05 ¾ / 4.059%98-14 / 4.262%98-05+ / 4.479%
    Spread to Benchmark Treasury:
    +60 bps+70 bps+80 bps
    Yield to Maturity:4.659%4.962%5.279%
    Price to Public:99.960% of the principal amount99.930% of the principal amount99.777% of the principal amount
    Net Proceeds to Issuer (before expenses):$647,465,000$646,945,000$695,289,000
    Optional Redemption Provisions:Make-whole and 1mo par call Make-whole and 2mo par call Make-whole and 3mo par call
    Make-Whole Call:
    Treasury Rate
    +10 bps
    Treasury Rate
    +15 bps
    Treasury Rate
    +15 bps
    Par Call:Beginning April 30, 2030 at parBeginning March 30, 2032 at parBeginning March 1, 2035 at par
    CUSIP/ISIN581557 BW4 / US581557BW49581557 BX2 / US581557BX22581557 BY0 / US581557BY05



    Trade Date:May 20, 2025
    Settlement Date**:May 30, 2025 (T+7)
    Joint Book-Running Managers:
    Barclays Capital Inc.
    BofA Securities, Inc.
    Deutsche Bank Securities Inc.
    J.P. Morgan Securities LLC
    PNC Capital Markets LLC
    Goldman Sachs & Co. LLC
    Senior Co-Managers:
    Citigroup Global Markets Inc.
    Wells Fargo Securities, LLC
    Co-Managers:
    BNP Paribas Securities Corp.
    HSBC Securities (USA) Inc.
    Scotia Capital (USA) Inc.
    TD Securities (USA) LLC
    Truist Securities, Inc.
    U.S. Bancorp Investments, Inc.
    ING Financial Markets LLC
    SG Americas Securities, LLC
    UniCredit Capital Markets LLC
    Mischler Financial Group, Inc.
    * Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. Each credit rating should be evaluated independently of any other credit rating.
    **Pursuant to Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers of the notes who wish to trade the notes on any date prior to the business day before delivery thereof will be required, by virtue of the fact that the notes initially will settle in T+7, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement.
    The Issuer has filed a registration statement (including a prospectus) with the Securities Exchange and Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. at +1 (888) 603-5847, BofA Securities, Inc. at +1 (800) 294-1322, Deutsche Bank Securities Inc. at +1 (800) 503-4611 and J.P. Morgan Securities LLC at +1 (212) 834-4533.



    No PRIIPs or UK PRIIPs KID - No PRIIPs or UK PRIIPs key information document (KID) has been prepared as the notes are not available to retail investors in the EEA or the UK.
    This pricing term sheet supplements the preliminary prospectus supplement dated May 20, 2025 and prospectus dated February 1, 2023. This communication should be read in conjunction with the preliminary prospectus supplement and the accompanying prospectus. The information in this communication supersedes the information in the preliminary prospectus supplement and the accompanying prospectus to the extent it is inconsistent with the information in such preliminary prospectus supplement or the accompanying prospectus.
    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED.  SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER ELECTRONIC MESSAGING SYSTEM.

    Get the next $MCK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on McKesson with a new price target

      Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

      12/4/24 7:43:38 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

      11/7/24 6:29:13 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

      9/24/24 8:19:53 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care